Heart disease, clinical proteomics and mass spectrometry.

Heart disease, clinical proteomics and mass spectrometry. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Heart disease, clinical proteomics and mass spectrometry. Abstract Text:

Brian A Stanley,Rebekah L Gundry,Robert J Cotter,Jennifer E Van Eyk,Brian A Stanley,Rebekah L Gundry,Robert J Cotter,Jennifer E Van Eyk,

Heart disease is the leading cause of mortality and morbidity in the world. As such, biomarkers are needed for the diagnosis, prognosis, therapeutic monitoring and risk stratification of acute injury (acute myocardial infarction (AMI)) and chronic disease (heart failure). The procedure for biomarker development involves the discovery, validation, and translation into clinical practice of a panel of candidate proteins to monitor risk of heart disease. Two types of biomarkers are possible; heart-specific and cardiovascular pulmonary system monitoring markers. Here we review the use of MS in the process of cardiac biomarker discovery and validation by proteomic analysis of cardiac myocytes/tissue or serum/plasma. An example of the use of MS in biomarker discovery is given in which the albumin binding protein sub-proteome was examined using MALDI-TOF MS/MS. Additionally, an example of MS in protein validation is given using affinity surface enhanced laser desorption ionization (SELDI) to monitor the disease-induced post-translational modification and the ternary status of myocyte-originating protein, cardiac troponin I in serum.

Heart disease, clinical proteomics and mass spectrometry. Publishing Authors By Initials

BA Stanley,RL Gundry,RJ Cotter,JE Van Eyk,BA Stanley,RL Gundry,RJ Cotter,JE Van Eyk,

For similar macromolecular substances: polymers: biopolymers: microfilament proteins: troponin: troponin i research abstracts see: macromolecular substances: polymers: biopolymers: microfilament proteins: troponin: troponin i research

PUBMED ID PMID:

MEDLINE DATE:

Heart disease, clinical proteomics and mass spectrometry. Journal Published:

PUBLICATION TYPE: Review

Journal: Disease markers

VOLUME: 20

Page Numbers: 167-78

Journal Abbreviation: Dis. Markers

ISSN: 0278-0240

DAY: 2

MONTH: 04

YEAR: 2004

Heart disease, clinical proteomics and mass spectrometry. Information

Number of References: 39

LANGUAGE: eng

NlmUniqueID: 8604127

Heart disease, clinical proteomics and mass spectrometry. Keywords Mesh Terms:

KEYWORDS: Troponin I

MESH TERMS: analysis

Chemical & Substance for Abstract: Heart disease, clinical proteomics and mass spectrometry. Information

Substance Name: Troponin I

Registry Number: 0

Grant and Affiliation Information for Heart disease, clinical proteomics and mass spectrometry.

AFFILIATION: Department of Medicine, Johns Hopkins University, Baltimore, MD 21224, USA.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Dis Markers

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Heart disease, clinical proteomics and mass spectrometry Related Publications

• A proteomic primer for the clinician.
• A rapid, economical, and reproducible method for human serum delipidation and albumin and IgG removal for proteomic analysis.
• Cardiovascular proteomics: past, present, and future.
• Expanding the subproteome of the inner mitochondria using protein separation technologies: one- and two-dimensional liquid chromatography and two-dimensional gel electrophoresis.
• Heart disease, clinical proteomics and mass spectrometry.
• Is familial hemiplegic migraine a hereditary form of basilar migraine?
• Optimization of cardiac troponin I pull-down by IDM affinity beads and SELDI.
• Optimization of paper bridge loading for 2-DE analysis in the basic pH region: application to the mitochondrial subproteome.
• Proteomic alterations in heat shock protein 27 and identification of phosphoproteins in ascending aortic aneurysm associated with bicuspid and tricuspid aortic valve.
• Proteomics of the aqueous humor in healthy New Zealand rabbits.